| Pharmos Corp. (NASDAQ:PARS)
is a biopharmaceutical company with research and development facilities
located in Rehovot, Israel and executive offices located in New Jersey.
The company has discovered, developed, and commercialized novel
therapeutics treating a range of neurological and inflammation-based
disorders - otherwise known as traumatic brain injuries (TBIs).
Putting an ironic twist on the cannabis plant’s stereotypical effects on
the central nervous system, the company has turned the plant towards
helping people think more clearly. Pharmos is developing its
cannabis-related compounds in such a way to eliminate marijuana's common
psychotropic effects, creating the potential to use them as a treatment
for central nervous system disorders. The lead candidate is dexanabinol
and their only real hope for success. Dexanabinol is in a pivotal trial
for treating Traumatic Brain Injury (TBI) and in Phase II for preventing
cognitive deterioration due to coronary bypass grafting surgery (CABG). |
 |
|
